SCHEMBL5215901

SCHEMBL5215901

O=C(Cl)c1csc(Cc2ccccc2Cl)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.46
ALDH1A1 P00352 3/20 0.46
LMNA P02545 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KMT2A Q03164 1/20 0.46
NAMPT P43490 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
PTGER1 P34995 1/20 0.44
MAPT P10636 5/20 0.43
NPC1 O15118 4/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
GAA P10253 1/20 0.42
GPR52 Q9Y2T5 1/20 0.40
MMP1 P03956 1/20 0.40
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5216024 0.88 MMP1 (0.52) RAB9AALDH1A1LMNAL3MBTL1SMN1; SMN2
SCHEMBL3054936 0.84 CDK5 (0.54) RAB9AALDH1A1LMNAL3MBTL1SMN1; SMN2
SCHEMBL5216804 0.81 MAPT (0.67) RAB9AALDH1A1LMNAL3MBTL1SMN1; SMN2
SCHEMBL4734963 0.80 HDAC1 (0.68) RAB9AALDH1A1LMNAL3MBTL1SMN1; SMN2
SCHEMBL14422215 0.79 LMNA (0.61) RAB9AALDH1A1LMNAL3MBTL1SMN1; SMN2
SCHEMBL14422208 0.77 LMNA (0.58) RAB9AALDH1A1LMNAL3MBTL1SMN1; SMN2
SCHEMBL14422209 0.76 LMNA (0.57) RAB9AALDH1A1LMNAL3MBTL1SMN1; SMN2
SCHEMBL4727539 0.73 MMP1 (0.49) RAB9AALDH1A1LMNAL3MBTL1SMN1; SMN2
SCHEMBL14422191 0.73 RAB9A (0.53) RAB9AALDH1A1LMNAL3MBTL1SMN1; SMN2
SCHEMBL11910626 0.72 HIF1A (0.52) RAB9AALDH1A1LMNAL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 US disclosed
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 US disclosed
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 US disclosed
EP-1818333-A1 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-08-15 EP disclosed
EP-1818333-A1 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-08-15 EP disclosed
EP-1603905-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2005-12-14 EP disclosed
WO-2004072068-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2004-08-26 WO disclosed
US-20040157845-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157845-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 RAB9A 1553/4885ALDH1A1 3103/4885LMNA 3914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.